A
A. Kashima
Publications - 4
Citations - 1678
A. Kashima is an academic researcher. The author has contributed to research in topics: Pharmacokinetics & Bioavailability. The author has an hindex of 2, co-authored 2 publications receiving 1519 citations.
Papers
More filters
Journal ArticleDOI
Crystal structure of human serum albumin at 2.5 A resolution.
TL;DR: A new triclinic crystal form of human serum albumin (HSA), derived either from pool plasma or from a Pichia pastoris expression system, was obtained from polyethylene glycol 4000 solution, and three-dimensional structures of pHSA and rHSA were determined.
Journal ArticleDOI
Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.
Daisuke Iijima,H. Sugama,Nobumasa Awai,Yoichi Takahashi,Yuko Togashi,Tohru Takebe,Jingkang Shen,Ying Ke,Hidenori Akatsuka,Takayuki Kawaguchi,Kei Takedomi,A. Kashima,Masashi Nishio,Yosuke Inui,Hikaru Yoneda,Guangxin Xia,Toru Iijima +16 more
TL;DR: A novel class of DRIs comprised of a 2-carbamoyl morpholine scaffold with a nonpeptidomimetic structure and a MW of <500 is introduced, which exerted a significant antihypertensive efficacy via oral administration on double transgenic mice carrying both the human angiotensinogen and the human renin genes.
Journal ArticleDOI
Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.
Daisuke Iijima,H. Sugama,Yoichi Takahashi,Miki Hirai,Yuko Togashi,Jing-shan Shen,Ying Ke,Hidenori Akatsuka,Takayuki Kawaguchi,Kei Takedomi,A. Kashima,Masashi Nishio,Yosuke Inui,Hikaru Yoneda,Guangxin Xia,Toru Iijima +15 more
TL;DR: In the efforts to improve the pharmacokinetic profile of 4 without a significant increase in the MW, the promising 2-carbamoyl morpholine derivative 4 (SPH3127), which demonstrated higher bioavailability and a more potent antihypertensive effect in preclinical models than aliskiren and has completed a phase II clinical trial for essential hypertension.